Metsera, Inc. (MTSR)
| Market Cap | 7.43B |
| Revenue (ttm) | n/a |
| Net Income | -314.41M |
| EPS | -4.20 |
| Shares Out | 105.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,908,901 |
| Open | 70.74 |
| Previous Close | 70.75 |
| Day's Range | 70.13 - 70.78 |
| 52-Week Range | 12.30 - 83.86 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2025 |
About MTSR
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Financial Performance
Financial StatementsNews
Pfizer Completes Acquisition of Metsera
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating...
Metsera shareholders vote for $10 billion acquisition by Pfizer
Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S. pharmaceutical giant re-entry into the lucrative obesity treatment market after a fierce bi...
Instacart Up on Earnings Beat; Metsera Down on Takeover Battle | Stock Movers
On this episode of Stock Movers with Lisa Mateo: - Metsera (MTSR) shares tank in premarket trading after Novo Nordisk A/S declined to further raise its offer for the US maker of an experimental weight...
Pfizer to buy Metsera in deal worth up to $10 billion
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted ...
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical de...
Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.
The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.
Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle
Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more than $10 billion following a heated takeover battle.
Novo Nordisk shares rise after dropping Metsera bid
Shares in Novo Nordisk NOVOb.CO rose in early trade on Monday, after the Wegovy-maker on Saturday dropped its bid for U.S. weight loss drug company Metsera, ending a bidding war with rival Pfizer.
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
Bagsværd, Denmark, 8 November 2025 – Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera. On 30 October 2025, Novo Nordisk announced the submission of an...
Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war
Pfizer prevails over rival Novo Nordisk after an unusual bidding war for the weight-loss startup.
Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer
Revised transaction values Metsera at up to $86.25 per share Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement a...
Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports
Pfizer has submitted a sweetened bid for obesity drug developer Metsera , as its fight against rival Novo Nordisk escalates, Bloomberg News reported on Friday.
Novo CEO says its bid for Metsera is higher
Novo Nordisk CEO Mike Doustdar said during a White House event on Thursday that the company's bid for obesity biotech Metsera is higher than the one from rival Pfizer Inc. , which has sued both Metser...
What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?
Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market.
Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle
A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 billion battle with U.S. rival Pfizer to win Metsera's obesity drug assets.
Metsera Issues Statement in Response to Litigation Ruling
NEW YORK , Nov. 5, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the Compa...
Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman
Evan David Seigerman, BMO, joins 'Fast Money' to talk bidding wars in the pharma space, Novo Nordisk dropping on earnings, and more.
Pfizer preparing to raise its bid for Metsera, WSJ reports
Pfizer is preparing to sweeten its offer again for Metsera , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk
Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk.
Delaware judge says she will not block Metsera from ending Pfizer deal
A Delaware judge said on Wednesday she would reject a request by Pfizer to temporarily block Metsera from terminating its takeover deal with Pfizer, allowing Metsera to proceed instead with a higher $...
Pfizer says it removed some conditions from its Metsera bid
Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Dela...
The Multi-Billion-Dollar Battle For Metsera's Obesity Drugs
In this week's edition of InnovationRx, we look at the battle for Metsera, the departure of FDA's top drug regulator, Kimberly-Clark's $40 billion Kenvue deal, and more. To get it in your inbox, subsc...
Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera
Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.
Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs
Novo Nordisk CEO Mike Doustdar joins 'Squawk Box' to discuss the company's quarterly earnings results, the company's bid for obesity biotech company Metsera, negotiations with the Trump administration...
Novo Nordisk CEO: Confident we will close Metsera deal
Novo Nordisk CEO Mike Doustdar tells CNBC he expects to close the company's takeover offer for Metsera. This as the company finds itself in a bidding war with Pfizer for U.S. biotech firm.